Envista (NYSE:NVST) posted its quarterly earnings results on Tuesday. The company reported $0.53 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.44 by $0.09, MarketWatch Earnings reports. Envista had a return on equity of 6.93% and a net margin of 5.00%. Envista updated its FY 2021 guidance to EPS.
Shares of NVST stock traded up $0.42 on Friday, hitting $41.17. 1,353,715 shares of the stock traded hands, compared to its average volume of 1,934,234. The company has a quick ratio of 0.77, a current ratio of 1.02 and a debt-to-equity ratio of 0.24. Envista has a twelve month low of $22.47 and a twelve month high of $46.52. The company’s 50-day moving average price is $42.77. The company has a market capitalization of $6.64 billion, a PE ratio of 60.54, a PEG ratio of 0.86 and a beta of 1.93.
Several equities research analysts have weighed in on NVST shares. Credit Suisse Group increased their price target on Envista from $49.00 to $55.00 and gave the stock an “outperform” rating in a research report on Thursday, May 6th. TheStreet raised Envista from a “d+” rating to a “c” rating in a report on Thursday, May 13th. Piper Sandler boosted their price target on Envista from $45.00 to $47.00 and gave the company a “neutral” rating in a report on Wednesday. Morgan Stanley raised their price objective on shares of Envista from $42.00 to $46.00 and gave the stock an “equal weight” rating in a research note on Friday, May 7th. Finally, Zacks Investment Research upgraded shares of Envista from a “hold” rating to a “strong-buy” rating and set a $52.00 target price for the company in a research note on Saturday, May 8th. Three equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. Envista currently has a consensus rating of “Buy” and an average price target of $43.67.
In related news, insider Curt W. Bludworth sold 9,207 shares of the business’s stock in a transaction dated Monday, June 7th. The shares were sold at an average price of $42.36, for a total value of $390,008.52. Following the sale, the insider now directly owns 66,025 shares in the company, valued at approximately $2,796,819. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Curt W. Bludworth sold 14,654 shares of the stock in a transaction dated Friday, June 11th. The stock was sold at an average price of $44.00, for a total transaction of $644,776.00. Following the transaction, the insider now directly owns 78,212 shares of the company’s stock, valued at approximately $3,441,328. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 40,192 shares of company stock valued at $1,750,670. 0.82% of the stock is owned by company insiders.
Envista Company Profile
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, and markets dental products in the United States and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company’s Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics, and dental eye loupes to oral surgeons, prosthodontists, and periodontists under the brands, including Nobel Biocare, Alpha Bio Tec, Implant Direct, Logon, Nobel Procera, and Orascoptic; and brackets and wires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Ormco, Insignia, AOA, and Spark brands.
Further Reading: Percentage Decliners
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Envista, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Envista wasn’t on the list.
While Envista currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.